CNOs must reduce agency spend by 30% by 2026/27. Switching a four‑hour infusion to a subcutaneous or low‑volume dose can return up to 3.5 hours of nursing time, a major lever for safer staffing. Directly Support Workforce Recovery CNOs must reduce agency spend by 30% by 2026/27. Switching a four‑hour infusion to a subcutaneous or low‑volume dose can return up to 3.5 hours of nursing time, a major lever for safer staffing.

Medication errors remain a top “Never Event”. With full Martha’s Rule compliance required by March 2027, pharma partners offering pre‑filled syringes and barcoded unit‑dosing directly support harm‑reduction priorities.

CNOs cannot approve virtual ward pathways if medicines are too complex to manage at home. With 40–50% of acute beds expected to become “virtual” by 2027, OPAT‑ready treatments are essential.

Your innovations can directly support the NHS Long Term Workforce Plan, the Neighbourhood Health Model and national safety requirements — all areas where nurse leaders hold significant influence.

Partnering connects you with CNOs, Directors of Nursing and senior clinical leaders who shape procurement, pathway redesign and system‑wide adoption of new medicines.

Pharmaceutical organisations that help reduce task‑heavy administration, prevent harm and enable community‑based care are seen not as suppliers, but as essential contributors to NHS recovery and reform.